Minimum wage increases lead to reductions in employer-sponsored insurance coverage in families with incomes below 300% of the federal poverty level.
The goal of this paper is to describe a protocol for a systematic expert panel process to inform the development of a clinical definition of neonatal abstinence syndrome.
This study examined receipt of services for mental health conditions and non-opioid substance use disorders among privately insured adolescents and young adults (ie, youth) with subsequent clinically diagnosed opioid use disorder or opioid poisoning.
In April 2021, 52% of unvaccinated adolescents aged 13–17 years and 56% of parents of unvaccinated adolescents aged 12–17 years reported intent for adolescent COVID-19 vaccination.
This report provides an independent assessment of the breadth, scope, and impact of health services and primary care research funded by the U.S. Department of Health and Human Services and U.S. Department of Veterans Affairs from FYs 2012 to 2018. The authors identify research gaps and offer recommendations for maximizing the outcomes and value of future investments in health services and primary care research by federal agencies.
Stakeholders reported that BIP participation had a range of impacts on the HCBS ecosystem, often beyond the structural reforms. Our findings highlight BIP impacts to monitor over the long term and to consider in evaluations of future rebalancing efforts.
We use three case examples to illustrate the importance of implementation financing strategies, which secure and direct funds to support Evidence-Based Practices adoption and continued use.
This guide prepares mental health practitioners to (1) identify clients with co-occurring opioid use and mental health disorders in mental health settings and (2) treat these clients with an appropriate opioid use disorder medication. It provides a practical strategy for treating clients in mental health settings with buprenorphine/naloxone or naltrexone extended-release injectable suspension.
Most people with co-occurring substance use and mental health disorders never get the high-quality care they need to recover. To address this issue, RAND researchers created a toolkit to support the delivery of effective, evidence-based pharmacotherapy for clients with co-occurring alcohol and/or opioid use and mental health disorders in mental health clinics.
RAND Health Care researchers used public and private data, such as data from health care claims, to understand telehealth's effect on health care delivery and how it affects care quality, access, equity, and costs.
This event, "Vaccine Confidence and Black Communities: Where do we go from here?", aimed to share lessons learned about COVID-19 vaccine messaging and access in order to reduce inequities.
High mistrust among Black Americans around COVID-19 vaccines may lower vaccine confidence.
The objective of this study is to describe and validate two claims-based urgent care centers definitions.
Although generic use has increased markedly over time in Part D, substantial variation across plans persists in a number of common therapeutic classes.
We developed and established the psychometric properties of survey measures describing normative and interpersonal integration.
This workshop provides an overview of key methodological challenges faced when evaluating the effectiveness of state-level policy using annual state-level data, as well as potential solutions and practice guidelines.
Organizational capacity and readiness constraints impede the delivery of medication treatment for alcohol use disorder in a large mental health system.
Chimeric antigen receptor (CAR)-T-cell therapy appears to be a promising treatment for B-cell and non-Hodgkin's lymphoma. CAR-T therapy effectiveness in the general population of patients may differ from effectiveness demonstrated in trials.
The authors propose four steps to reduce racial and ethnic disparities in Medicare-based quality-incentive programs in the United States.
Drawing on national retail pharmacy data, researchers identified and categorized clinicians who prescribed buprenorphine for OUD at least once between January 2017 and December 2018.
